COVID-19

COVID-19 BIOPHARMA
RESOURCES

Mayo Clinic has made a historic investment to help the world respond to COVID-19, leading the way in research, testing, and industry partnerships to help make needed therapies available to those who need it most.

AVAILABLE TESTING TO SUPPORT COVID-19

BioPharma Diagnostics is providing the following tests to support research for both vaccine and therapy development. Our testing enables research by providing key information to understand disease status among patient populations. Links go to specifics in the Mayo Clinic Laboratories test catalog.

MAYO CLINIC'S COVID-19 RESPONSE

4.9M

4.9M MOLECULAR TESTS PERFORMED AS OF SEPTEMBER 1

48

48 STATES SENDING COVID-19 TESTING TO MAYO CLINIC

50+

50+ INFECTIOUS DISEASE PHYSICIANS AND SCIENTISTS

3

3 WEEKS IT TOOK MAYO TO DEVELOP A PCR LDT

COVID-19 TESTS

MOLECULAR TESTING


Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Detection, Varies (Qualitative)

Useful for detection of COVID-19 due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) RNA Detection and Quantification, Varies

Useful for the detection and quantification of severe respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19); useful for serial monitoring of SARS-CoV-2 RNA concentrations in the upper respiratory tract of individuals receiving antiviral or immune therapy. For more information, contact us.

SEROLOGY TESTING


Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) IgG Antibody, Serum

Useful for detection of IgG-class antibodies against SARS-CoV-2, the virus that causes COVID-19.

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Total Antibody, Serum

Useful for aiding the identification of individuals with an adaptive immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), indicating recent or prior infection. For more information, contact us.